ATE420867T1 - Phenylpyridazin derivative als liganden für gaba- rezeptoren - Google Patents

Phenylpyridazin derivative als liganden für gaba- rezeptoren

Info

Publication number: ATE420867T1
Authority: AT; Austria
Prior art keywords: ligands; gaba receptors; phenylpyridazine derivatives; phenylpyridazine; derivatives
Prior art date: 2002-08-13

Application number

AT03784243T

Other languages

English (en)

Inventor

Wesley Peter Blackaby

Peter Blurton

Frank Burkamp

Stephen Robert Fletcher

Andrew Jennings

Richard Thomas Lewis

Angus Murray Macleod

Leslie Joseph Street

Steve Thomas

Niel Monique Bodil Van

Kevin Wilson

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-13

Filing date

2003-08-04

Publication date

2009-01-15

2002-08-13 Priority claimed from GB0218874A external-priority patent/GB0218874D0/en

2002-12-19 Priority claimed from GB0229591A external-priority patent/GB0229591D0/en

2003-08-04 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE420867T1 publication Critical patent/ATE420867T1/de

Links

239000003446 ligand Substances 0.000 title abstract 2
XWSSUYOEOWLFEI-UHFFFAOYSA-N 3-phenylpyridazine Chemical class C1=CC=CC=C1C1=CC=CN=N1 XWSSUYOEOWLFEI-UHFFFAOYSA-N 0.000 title 1
102000005915 GABA Receptors Human genes 0.000 title 1
108010005551 GABA Receptors Proteins 0.000 title 1
VYPDRJDYVPYUJY-UHFFFAOYSA-N 4-phenylpyridazine Chemical class C1=CC=CC=C1C1=CC=NN=C1 VYPDRJDYVPYUJY-UHFFFAOYSA-N 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
230000036461 convulsion Effects 0.000 abstract 1
229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

AT03784243T 2002-08-13 2003-08-04 Phenylpyridazin derivative als liganden für gaba- rezeptoren ATE420867T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0218874A GB0218874D0 (en)	2002-08-13	2002-08-13	Therapeutic agents
GB0229591A GB0229591D0 (en)	2002-12-19	2002-12-19	Therapeutic agents

Publications (1)

Publication Number	Publication Date
ATE420867T1 true ATE420867T1 (de)	2009-01-15

Family

ID=31716927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03784243T ATE420867T1 (de)	2002-08-13	2003-08-04	Phenylpyridazin derivative als liganden für gaba- rezeptoren

Country Status (8)

Country	Link
US (1)	US20060235021A1 (de)
EP (1)	EP1532120B1 (de)
JP (1)	JP2006507237A (de)
AT (1)	ATE420867T1 (de)
AU (1)	AU2003246979B8 (de)
CA (1)	CA2495285A1 (de)
DE (1)	DE60325865D1 (de)
WO (1)	WO2004014865A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1812071A2 (de)	2004-10-13	2007-08-01	PTC Therapeutics, Inc.	Verbindungen zur nonsense-unterdrückung und verwendung dieser verbindungen für die herstellung eines medikaments zur behandlung somatischer mutationsbedingter erkrankungen
US8258136B2 (en) *	2005-12-07	2012-09-04	Sumitomo Chemical Company, Limited	Pyridazine compound and use thereof
US7465795B2 (en)	2005-12-20	2008-12-16	Astrazeneca Ab	Compounds and uses thereof
WO2007073283A1 (en)	2005-12-20	2007-06-28	Astrazeneca Ab	Substituted cinnoline derivatives as gabaa-receptor modulators and method for their synthesis
CA2718241A1 (en) *	2008-03-11	2009-09-17	Neurosearch A/S	Novel triaryl derivatives useful as modulators of nicotinic acetylcholine receptors
EP2640391B1 (de) *	2010-11-15	2015-11-11	Agenebio, Inc.	Pyridazinderivate, zusammensetzungen und verfahren zur behandlung von kognitiven störungen
US20150374705A1 (en)	2012-02-14	2015-12-31	Shanghai Institues for Biological Sciences	Substances for treatment or relief of pain
EP3083569B1 (de)	2013-12-20	2022-01-26	Agenebio, Inc.	Benzodiazepinderivate, zusammensetzungen und verfahren zur behandlung von kognitiven störungen
CN104356053B (zh) *	2014-10-21	2017-01-18	天津大学	2‑(3‑卤素苯基)吡啶类衍生物的制备方法
IL256354B (en)	2015-06-19	2022-09-01	Agenebio Inc	Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment
NZ750414A (en) *	2016-07-05	2023-02-24	Guangzhou Maxinovel Pharmaceuticals Co Ltd	Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt)	2016-12-19	2019-11-26	Agenebio, Inc.	derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
WO2019128918A1 (zh)	2017-12-29	2019-07-04	广州再极医药科技有限公司	芳香乙烯或芳香乙基类衍生物、其制备方法、中间体、药物组合物及应用
MX2020013927A (es)	2018-06-19	2021-03-02	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
WO2024148148A1 (en) *	2023-01-04	2024-07-11	The Trustees Of Columbia University In The City Of New York	Pyridazine based small molecule inhibitor of cognitive impairment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2510998B1 (fr) *	1981-08-07	1986-01-10	Sanofi Sa	Nouveaux derives amines de la pyridazine, leur procede de preparation et les medicaments, a action desinhibitrice, qui en comportent
FR2562071B1 (fr) *	1984-03-30	1986-12-19	Sanofi Sa	Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
CZ18199A3 (cs) *	1996-07-25	1999-06-16	Merck Sharp And Dohme Limited	Triazolopyridazinové deriváty, způsob výroby a farmaceutický prostředek
AP2003002762A0 (en) *	2000-09-15	2003-03-31	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors
ATE310740T1 (de) *	2000-11-10	2005-12-15	Merck Sharp & Dohme	Imidazotriazin-derivate als liganden für gaba- rezeptoren

2003
- 2003-08-04 AT AT03784243T patent/ATE420867T1/de not_active IP Right Cessation
- 2003-08-04 CA CA002495285A patent/CA2495285A1/en not_active Abandoned
- 2003-08-04 DE DE60325865T patent/DE60325865D1/de not_active Expired - Lifetime
- 2003-08-04 US US10/524,173 patent/US20060235021A1/en not_active Abandoned
- 2003-08-04 EP EP03784243A patent/EP1532120B1/de not_active Expired - Lifetime
- 2003-08-04 JP JP2004527013A patent/JP2006507237A/ja not_active Withdrawn
- 2003-08-04 WO PCT/GB2003/003376 patent/WO2004014865A1/en not_active Ceased
- 2003-08-04 AU AU2003246979A patent/AU2003246979B8/en not_active Ceased

Also Published As

Publication number	Publication date
AU2003246979B2 (en)	2009-07-23
US20060235021A1 (en)	2006-10-19
DE60325865D1 (de)	2009-03-05
WO2004014865A1 (en)	2004-02-19
JP2006507237A (ja)	2006-03-02
AU2003246979B8 (en)	2009-08-06
EP1532120A1 (de)	2005-05-25
EP1532120B1 (de)	2009-01-14
CA2495285A1 (en)	2004-02-19
AU2003246979A1 (en)	2004-02-25

Legal Events

Date	Code	Title	Description
2009-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60325865D1 (de)	2009-03-05	Phenylpyridazin derivative als liganden für gaba-rezeptoren
GB0212048D0 (en)	2002-07-03	Therapeutic agents
ATE310740T1 (de)	2005-12-15	Imidazotriazin-derivate als liganden für gaba- rezeptoren
DE60012044D1 (de)	2004-08-12	Imidazopyridinderivate als liganden für gaba-rezeptoren
DE60214532D1 (de)	2006-10-19	Imidazopyrimidin-derivate als liganden für gaba-rezeptoren
ATE310002T1 (de)	2005-12-15	Imidazotriazin-derivate als gaba-rezeptor- liganden
DE60307462D1 (de)	2006-09-21	8-fluorimidazo(1,2-a)pyridin derivative als liganden für gaba rezeptoren
DE69936998D1 (de)	2007-10-11	Pyrazolotriazinderivate als gaba-rezeptorliganden
DE60335869D1 (de)	2011-03-10	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
DE60205101D1 (de)	2005-08-25	Imidozo-pyrimidine derivate als liganden für gaba rezeptoren
DE60006835D1 (de)	2004-01-08	Imidazopyridinderivate als gaba rezeptor liganden
NO20076344L (no)	2008-02-27	Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
ATE253066T1 (de)	2003-11-15	Imidazotriazinderivate als gaba rezeptor-liganden
ATE399168T1 (de)	2008-07-15	Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
ATE449082T1 (de)	2009-12-15	(3,4-dihydro-chinazolin-2-yl)-(2-aryloxy-ethyl) amine mit aktivität am 5-ht-rezeptor
TW200609218A (en)	2006-03-16	Bicyclic compounds
DE60319989D1 (de)	2008-05-08	Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
ATE359269T1 (de)	2007-05-15	4-arylsulphonylpiperidin-derivate als 5-ht2a - rezeptor antagonisten
MY139258A (en)	2009-09-30	Carbamoyl-type benzofuran derivatives
ATE414692T1 (de)	2008-12-15	Pyridinketone mit herbizideffekt
EA200300084A1 (ru)	2003-06-26	Производные индола, пригодные для лечения расстройств цнс
SE0403084D0 (sv)	2004-12-17	Chemical process
DK1419167T3 (da)	2005-06-13	1-(2,5'-anhydro-lyxofuranosyl) thyminer til syntese af radiomarkerede fluor-3 doxynucleotider
EA200300019A1 (ru)	2003-04-24	Производные индола, пригодные для лечения расстройств цнс
TR200401185T4 (tr)	2004-06-21	Yeni piridazin endotelin antagonistleri